EMA dilutes ambitious data re-analysis plans
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has abandoned plans to routinely require and re-analyze original clinical trial data in marketing authorization applications. Instead, it is considering whether it should restrict this exercise to a limited number of cases where "such analysis could significantly strengthen the [EMA's] assessment work".